Methyl-2-pivaloylbenzoat | 32025-39-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Methyl-2-pivaloylbenzoat
• 英文别名: 2-Pivaloylbenzoesaeuremethylester；Methyl 2-pivaloylbenzoate；methyl 2-(2,2-dimethylpropanoyl)benzoate
• CAS: 32025-39-1
• 化学式: C₁₃H₁₆O₃
• 分子量: 220.268
• InChiKey: OKSNPPHLJDENEH-UHFFFAOYSA-N

物化性质

• 沸点：
  319.008±25.00 °C(Press: 760.00 Torr)(predicted)
• 密度：
  1.057±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Methyl-2-pivaloylbenzoat 在 sodium hydroxide 、 氨 、 溴 作用下， 以 甲醇 为溶剂， 生成 1-(2-aminophenyl)-2,2-dimethylpropan-1-one
  参考文献：
  名称：

  Bettembourg,M.-C.; Brunesseaux,Y., Bulletin de la Societe Chimique de France, 1963, p. 2449 - 2451

  摘要：

  DOI：

文献信息

• SUBSTITUTE DIPHENYLAMINE COMPOUNDS USE THEREOF AS ANTITUMOR AGENTS
  申请人：SINOCHEM CORPORATION

  公开号：US20150011628A1

  公开（公告）日：2015-01-08

  The invention relates to substituted diphenylamine compounds using as antitumor agents. The structure of the compounds is represented as the general formula (I): The groups are as defined as specification. The compound represented by formula (I) showed potent antitumor activity, especially to cure or alleviate the cancer causing by cancer cells of human tissue or organ. The preferred cancers are: colon cancer, liver cancer, lymph cancer, lung cancer, esophageal cancer, breast cancer, central nervous system cancer, melanoma, ovarian cancer, cervical cancer, renal cancer, leukemia, prostatic cancer, pancreatic cancer, bladder cancer, rectal cancer, osteosarcoma, nasopharynx cancer or stomach cancer.

  该发明涉及以取代二苯胺化合物作为抗肿瘤药剂。化合物的结构表示为通式(I)：其中各个基团如规范所定义。由通式(I)表示的化合物显示出强效的抗肿瘤活性，特别是用于治疗或缓解由人体组织或器官的癌细胞引起的癌症。首选的癌症包括：结肠癌、肝癌、淋巴癌、肺癌、食管癌、乳腺癌、中枢神经系统癌、黑色素瘤、卵巢癌、宫颈癌、肾癌、白血病、前列腺癌、胰腺癌、膀胱癌、直肠癌、骨肉瘤、鼻咽癌或胃癌。
• CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
  申请人：Hammock D. Bruce

  公开号：US20070225283A1

  公开（公告）日：2007-09-27

  Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

  提供了可抑制可溶性环氧化物水解酶（sEH）的抑制剂，这些抑制剂结合了多种药效团，并且在治疗疾病方面具有用途。
• Substituted Diphenylamine Compounds, Preparation Method and Use Thereof
  申请人：Liu Changling

  公开号：US20120309844A1

  公开（公告）日：2012-12-06

  Substituted diphenylamine compounds of general formula I are provided, in which each substituted group is defined as in the description. The compounds of general formula I have broad-spectrum fungicidal activity in the field of agriculture. Furthermore, the preparation methods of the above compounds are simple.

  提供了一般式I的取代二苯胺化合物，其中每个取代基在描述中有定义。一般式I的化合物在农业领域具有广谱杀菌活性。此外，上述化合物的制备方法是简单的。
• THIAZOLE OREXIN RECEPTOR ANTAGONISTS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160185768A1

  公开（公告）日：2016-06-30

  The present invention is directed to thiazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thiazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及噻唑化合物，其为促进睡眠的药物。本发明还涉及上述噻唑化合物在预防或治疗神经和精神障碍及疾病中的应用，其中促进睡眠的药物与促进睡眠的药物有关。本发明还涉及含有这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗与促进睡眠的药物有关的疾病中的应用。
• Piperidine isoxazole and isothiazole orexin receptor antagonists
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10017504B2

  公开（公告）日：2018-07-10

  The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. Such compounds are of the general structural formula I: wherein the variables are defined herein. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及哌啶异恶唑和异噻唑奥曲肽化合物，它们是奥曲肽受体的拮抗剂。此类化合物的结构通式为 I： 其中变量的定义见本文。 本发明还涉及本文所述化合物在潜在治疗或预防涉及奥曲肽受体的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在预防或治疗涉及奥曲肽受体的此类疾病中的用途。